Humacyte Inc (HUMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Humacyte Inc (HUMA) has a cash flow conversion efficiency ratio of -8.403x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.12 Million) by net assets ($3.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see HUMA market cap overview for the company's overall valuation and market capitalisation.
Humacyte Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Humacyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Humacyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Humacyte Inc ranked by their cash flow conversion efficiency. Explore Humacyte Inc (HUMA) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aemetis Inc
NASDAQ:AMTX
|
0.039x |
|
UBM Development AG
VI:UBS
|
0.009x |
|
Inspired Entertainment Inc
NASDAQ:INSE
|
-1.891x |
|
Globe Union Industrial Corp
TW:9934
|
0.044x |
|
Cheops Technology France SA
PA:MLCHE
|
N/A |
|
Apyx Medical Inc
NASDAQ:APYX
|
-0.315x |
|
FACT II Acquisition Corp. Class A Ordinary Shares
NASDAQ:FACT
|
-0.001x |
|
Neumora Therapeutics, Inc.
NASDAQ:NMRA
|
-0.353x |
Annual Cash Flow Conversion Efficiency for Humacyte Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Humacyte Inc from 2019 to 2025. View current stock price of Humacyte Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.11 Million | $-105.04 Million | -33.786x | -1913.56% |
| 2024-12-31 | $-52.67 Million | $-98.12 Million | 1.863x | +134.43% |
| 2023-12-31 | $13.55 Million | $-73.31 Million | -5.412x | -789.60% |
| 2022-12-31 | $116.93 Million | $-71.13 Million | -0.608x | +8.46% |
| 2021-12-31 | $122.17 Million | $-81.19 Million | -0.665x | +15.48% |
| 2020-12-31 | $70.67 Million | $-55.57 Million | -0.786x | -44.80% |
| 2019-12-31 | $132.20 Million | $-71.79 Million | -0.543x | -- |
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to b… Read more